chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Pt vaccinated with Pneumovax 23 injection site was red, swollen & painful. Treated w/Ceclor and he recovered.
I have abdominal pain that is yet unresolved. I have an appointment with my primary care to address that issue. I also have a rash that started in may. I have used an oral steroid pack to help. This was given to me from a walk in urgent care.  It helped temporarily. I also have cortisone cream i use everyday to try and help with the rash. The pain and rash started in may and have not resolved.
Brief but intense dizziness and nausea ~12 hours after the shot, followed by persistent fever, aches, chills, and a very sore arm. Symptoms resolved ~36 hours after the shot.
Approx 5 mins p/recvd vax, pt had red blotchy areas over face & hairline; lt thigh markedly reddened around inject site; pt crying, unable to be comforted; red blotchiness extended to both arms; ice pack applied to lt leg; DPH given;
10/12/2011 Received vaccine from my place of employment. I was 16 weeks pregnant at the time. Immediate reaction was a sore arm for next 24 hours. 10/20/2011 At an OB appointment, the doctor was not able to detect a fetal heartbeat and informed me that my baby had died. The ultrasound showed that the baby had stopped growing a few days ago. They were able to determine the approximate date of death by measuring the fetus.
Came to see PCP on 4/8/21: Left Shoulder pain- she had a steroid injection in this shoulder years ago for pain, but the pain returned after she received her first COVID vaccine in that arm. Referred to Physical Therapy.  Patient also c/o "hot flashes in her back" She was rx Lyrica.
Dizzy and Faint, pt seated and given a cold pack with orange juice and crackers.  Outcome: pt reports feeling "better than before" after 15 minutes.
This spontaneous case was reported by a consumer and describes the occurrence of DISCOMFORT (uncomfortable), INSOMNIA (cant sleep), PAPULE (a little bump on her arm, not red nor inflamed), PAIN IN EXTREMITY (Pain on left arm) and PRURITUS (but 3 days ago terrible itchy) in an 84-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 013F21A, 038A21A and 014M20A) for COVID-19 vaccination. Concurrent medical conditions included Blood disorder and Heart disorder (Heart problem).On 01-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form.On 30-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form.On 22-Nov-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 24-Nov-2021, the patient experienced DISCOMFORT (uncomfortable), INSOMNIA (cant sleep), PAPULE (a little bump on her arm, not red nor inflamed), PAIN IN EXTREMITY (Pain on left arm) and PRURITUS (but 3 days ago terrible itchy). At the time of the report, DISCOMFORT (uncomfortable), INSOMNIA (cant sleep), PAPULE (a little bump on her arm, not red nor inflamed), PAIN IN EXTREMITY (Pain on left arm) and PRURITUS (but 3 days ago terrible itchy) outcome was unknown. Patient did  not taken any medications yet.Patient is on NSAID Reported as Concomitant medication. 3 days ago patient had all the events.
Shaking, fever, chills, headache. Painful muscle aching. From 2 hrs after injection until Wednesday, March 15, 2023. Red rash at site of injection on my arm to my elbow. Itchy.
ache: joint, acid reflux, anxiety, arrhythmia, high cholesterol, leg cramps, dry mouth, energy loss, muscle fatigue, gastritis, migraines, loud noises, lump in right groin, anxious, angry, irritable mood, numbness tingling fingers, pain lower back, groin, back, joint and muscle, chest, rashes, sleep problem, thirst and tiredness
OVER THE COURSE OF 2 MONTHS...   -Poor circulation in lower left arm.  -throbbing/poor circlation in right leg -fatigue -could not sleep -constipation
Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021; Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021; This spontaneous case was reported by an other health care professional and describes the occurrence of POOR QUALITY PRODUCT ADMINISTERED (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) and PRODUCT TEMPERATURE EXCURSION ISSUE (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) in a 57-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 031A21A) for COVID-19 immunisation.     No Medical History information was reported.    On 20-Mar-2021 at 4:57 AM, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .5 milliliter. On 20-Mar-2021 at 4:57 AM, the patient experienced POOR QUALITY PRODUCT ADMINISTERED (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021). In 2021, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021). At the time of the report, POOR QUALITY PRODUCT ADMINISTERED (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) and PRODUCT TEMPERATURE EXCURSION ISSUE (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Age of patient was reported as 57.87 for dose administered on 20-Mar-2021, Vaccination time 4:57 PM. No concomitant medications were reported. Batch number 031A21A underwent temperature excursion on 20-Mar-2021 with temperature 37 degrees Fahrenheit from 09:00 Am to 10 AM.  This vial was moved to fridge on 09-Mar-2021. beyond use date for the vial was reported as 08-Apr-2021. Product moved to clinic on 20-Mar-2021. Vial was in cooler storage and was not in frozen storage during high-pace COVID-19 vaccination at around 2021. Vials were only punctured right before administration. Vaccines were not frozen at time of administration. It was reported that each time a vial was put into a cooler, sometimes there was a period of 1 hour or 1 hour and a half approximately, when temperature data logger registered a temperature of 34- or 35-degree Fahrenheit. Temperature recordings were taken using a traceable temperature monitor at every hour. No treatment medications were reported.
pt recvd vax;3 days later devel a total of approx 100 lesions over face,trunk & extremities;dx as chicken pox;also warm to touch w/ sl fever;no evidence of exposure; to md for eval;
Fever, chills, aches about 24 hours of injection. Large area of erythema at injection site (T. 99 in office).
Patient received a booster dose of 0.25ml from the booster dose only vial presentation with the middle set of  number of 275 instead of the recommended dosage of 0.5ml; This spontaneous case was reported by a pharmacist and describes the occurrence of INCORRECT DOSE ADMINISTERED (Patient received a booster dose of 0.25ml from the booster dose only vial presentation with the middle set of  number of 275 instead of the recommended dosage of 0.5ml) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 14-Jul-2022, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .25 milliliter. On 14-Jul-2022, the patient experienced INCORRECT DOSE ADMINISTERED (Patient received a booster dose of 0.25ml from the booster dose only vial presentation with the middle set of NDC number of 275 instead of the recommended dosage of 0.5ml). At the time of the report, INCORRECT DOSE ADMINISTERED (Patient received a booster dose of 0.25ml from the booster dose only vial presentation with the middle set of number of 275 instead of the recommended dosage of 0.5ml) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications were reported. Treatment information was unknown.
Menstrual bleeding in post menopausal woman. For about 1 week after injection and then restarted 17 days after injection.  Restart is heavier than initial. Today is 1st day of restart; This is a spontaneous report from a contactable consumer (patient).   A 56-year-old non-pregnant female patient received bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Formulation: Solution for injection, Lot Number: 8730), via an unspecified route of administration, administered in Left arm on 29Mar2021 18:30 at the age of 56-years-old as dose 1, single for covid-19 immunisation. The patient's medical history and concomitant medications were not reported. The patient had no known allergies. Facility type vaccine was pharmacy or drug store. The patient did not receive other vaccine in four weeks of vaccination. The patient was not diagnosed with COVID-19 prior vaccination. The patient has not been tested for COVID-19 post vaccination. On 31Mar2021, the patient experienced Menstrual bleeding in post-menopausal woman. For about 1 week after injection and then restarted 17 days after injection. Restart is heavier than initial. Today is 1st day of restart. No treatment was received for adverse event. The outcome of event was not recovered.  No follow-up attempts are possible. No further information is expected.
Frozen shoulder - left shoulder. Pain, stiffness, diminished range of motion in shoulder joint
Sudden & constant diarrhea for over a week, stomach pain, dizziness, fever
After administration of vaccine pt. developed swelling in (L) upper arm and warm to touch, with pain radiating to her neck. Swelling is beginning to go down.
my left arm swelled up from my neck and left breast  plate area to fingers to the first knuckle/ pain/ numbness/unable to hold objects/this was a booster shot
Second dose of Rabies vaccine administered 5/31/06 at 10 am, at 11am felt anxiety, and palpatations, then achy all over. At 5 pm felt feverish(did not take temperature)and generalized aches even bottom of feet, some chills, at 6 pm took tylenol, awoke at 3 am with headache and took more tylenol, at 10 am today 6/1/06 have slight headache, but much improved.
roll all over, noted 13JUn as urticaria but poss erythema multiforme; by 14JUN it was dx as widespread erythema multiforme w/ecchymosis; all over body; itch, swelling & 1 1/2 lbs edema documented;
pt recvd vax; 5 days later, exp petechiae rash on upper torso & arms;unresolved
That afternoon, my arm started to hurt. During the  night, I got chills - shaking chills. Night sweats and fever, as well. I took Motrin every 4 hours. I had to keep Taking Motrin every four hours because the chills were so bad. Monday, at 04:00 am it ended. I was up sweating but then it was done.
Patient incorrectly received Covid-19 monovalent vaccine. Patient should have received Covid-19 bivalent vaccine. Patient completed initial series on: 3/32/21, 4/13/21, and initial booster on 12/9/21.
Information has been received from a nurse concerning a female (age unknown) with warts on feet, who was vaccinated (route unknown) on an unspecified date with her first dose of GARDASIL (lot# not reported).  The nurse reported that the patient had three large warts on her foot that cleared up 4-5 days after she received the vaccination.  Unspecified medical attention was not sought.  No product quality complaint was involved.  Additional information has been requested.
Inappropriate age vaccine administration; This spontaneous case was reported by a nurse and describes the occurrence of PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (Inappropriate age vaccine administration) in a 16-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 008C21A and 021C21A) for COVID-19 vaccination.     No Medical History information was reported.   On 29-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 02-Jun-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 29-Apr-2021, the patient experienced PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (Inappropriate age vaccine administration). On 29-Jun-2021, PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (Inappropriate age vaccine administration) had resolved.        mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosing remained unchanged.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medications were reported.  Treatment information was not provided.   This case was linked to MOD-2021-271069 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 08-Jul-2021: Follow-up  received on 08-JUL-2021, updated information includes:Reporter information, patient's second dose details were provided. On 28-Jul-2021: Non-significant Follow up appended for document attachement
I got tired; Kind of emotionally, kind of mentally little feeling kind of off; The night I got it, my feet turned red, my toes and mostly the toes but the feet was like red; does not look right; It is kind of like prickly now, it doesn't hurt so much, it just doesn't feel right the feet down; my hands are a little prickly too; This is a spontaneous report from a contactable consumer or other non hcp. A female patient of an unspecified age received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, formulation: Solution for injection, Batch/Lot number was not reported) dose number unknown via an unspecified route of administration on an unspecified date as single dose for covid-19 immunisation. Medical history included frostbite from an unknown date and unknown if ongoing I have frostbite (Medical History) in my hands and feet when I was a kid. The patient's concomitant medications were not reported. On an unspecified date the patient experienced i got tired, kind of emotionally, kind of mentally little feeling kind of off, the night i got it, my feet turned red, my toes and mostly the toes but the feet was like red; does not look right, it is kind of like prickly now, it doesn't hurt so much, it just doesn't feel right the feet down; my hands are a little prickly too. Clinical course was reported as she had the shot (Pfizer Covid-19 Vaccine), last Thursday and she felt great the first day and the second day she got tired, kind of emotionally, kind of mentally little feeling kind of off but then when she got it, the night she got it my feet turned red, my toes and mostly the toes but the feet was like red then she showed it to my husband also said does not look right and then it is kind of like prickly now, it doesn't hurt so much, it just doesn't feel right the feet down and my hands are a little prickly too and she has frostbite (Medical History) in her hands and feet when she was a kid. So, she doesn't know if it has anything to do with but is that pretty much a normal reaction. The clinical outcome of the event was unknown.  No follow-up attempts are possible; information about lot/batch number cannot be obtained.
Pt had a negative pregnancy test on 22 May 18. Pt received Anthrax dose #2 on 1 June 2018.  Pt reports she had a positive home pregnancy test at the end of June 2018 (Exact Date unknown).
PHARMACIST ADMINISTERED LOWER THAN AUTHORIZED DOSE ON 9/2/22. PHARMACIST GAVE 0.25ML DOSE OF BIVALENT MODERNA, PT SHOULD HAVE RECIEVED 0.5ML. PT WILL BE RETURNING TODAY (9/6/22) FOR READMINISTRATION WITH CORRECT DOSE.
This case was reported by a consumer (also the subject's daughter) and described the occurrence of whooping cough in a 79-year-old female subject who was vaccinated with DTPa ((with small D + P), manufacturer unspecified). A physician or other health care professional has not verified this report. Concurrent medical condition included shingles 10 days after shingle vaccine in the fall of 2011. Concurrent vaccination included Influenza vaccine unspecified; manufacturer unspecified; unknown; unknown given "around Thanksgiving" in November 2011. Previous vaccination included varicella virus vaccine (non-gsk); non-GSK manufacturer; unknown, unknown given in the fall of 2011. Concurrent medications included LIPITOR, Lisinopril and PREVACID. On an unspecified date in November 2011 "around Thanksgiving", the subject received a dose of DTPa (with small D + P) (details unknown). It was reported that the subject received a "whooping cough vaccine". On an unspecified date prior to 26 January 2012, within months of vaccination with DTPa (with small D + P), the subject experienced cough and "snot running down throat". On unspecified dates, the subject was treated with antibiotics (unspecified) and the symptoms became worse. On 26 January 2012, approximately 2 months after vaccination with DTPa (with small D + P), the subject was seen by an allergist and was diagnosed with whooping cough. This report is considered a vaccination failure. The subject's daughter reported she felt that her mother "probably already had whooping cough before she ever got the vaccine". This case was assessed as medically serious by GSK. At the time of reporting, the outcome of the whooping cough was unknown.
was experiencing numbness in her face; This spontaneous report as received from a nurse prescriber via a company representative refers to a non-pregnant female patient of unknown age. No information regarding the patient's pertinent medical history, concomitant medications, drug reactions and allergies was provided.  On 15-APR-2020, the patient was vaccinated with a dose of hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) injection (dose, route of administration, lot number and expiration date were not reported) as routine vaccination. On the same date, the patient contacted the physician office and informed that she experienced numbness in her face. The outcome of the event was not reported.  The relatedness between numbness in the patient's face and hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) was not provided.
50 year old patient who did not have insurance and was ordered GARDASIL 9; Gardasil for EDV disease; This spontaneous report was received from a nurse via company representative referring to a 50-year-old patient of unknown gender. The patient's concurrent condition included an insurance issue; patient's pertinent medical history, concomitant medications and previous drug reactions or allergies were not provided.   On an unknown date, the patient may have been vaccinated with hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) for epidermodysplasia verruciformis (EDV) disease (product administered to patient of inappropriate age and product use in unapproved indication) (strength, dose, scheme of vaccination, route of administration, anatomical location were not reported; lot number and expiration date  were unknown by the reporter).
fatigue; injection site pain; given 0.3mL even thought it was supposed to be 0.2mL; Received dose of vaccination that was not diluted; This is a spontaneous report received from contactable reporter(s) (Pharmacist) from medical information team.  A 10-year-old female patient received BNT162b2 (BNT162B2), on 04Jun2022 as dose 3 (booster), 0.3ml single (Lot number: FL2757, Expiration Date: 03Aug2022) at the age of 10 years intramuscular, in left deltoid for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Covid-19 vaccine (manufacture unknown , Primary series vaccination), for covid-19 immunization. The following information was reported: FATIGUE (non-serious) with onset 04Jun2022, outcome "unknown"; VACCINATION SITE PAIN (non-serious) with onset 04Jun2022, outcome "unknown", described as "injection site pain". PRODUCT PREPARATION ERROR (non-serious) with onset 04Jun2022, outcome "unknown", described as "Received dose of vaccination that was not diluted";OVERDOSE (non-serious) with onset 04Jun2022, outcome "unknown", described as "given 0.3mL even thought it was supposed to be 0.2mL"; Therapeutic measures were not taken as a result of fatigue, vaccination site pain. Additional information: The pharmacist calling to report that they vaccinated a ten-year-old female with the correct orange cap formulation, but it was not diluted. This was the booster dose. The patient was given 0.3mL even thought it was supposed to be 0.2mL.After follow up with patients parent, patient had injection site pain and fatigue. States the patient has improved. Reporter stated that It was just an error, not the fault of the packaging or the vaccine.He doesn't think any medications would have contributed to the injection site pain or fatigue, if she take any he doesn't think it's relevant.
No adverse event; Patient administered the 2nd bivalent dose to a patient 6 weeks after the 1st one instead of 8 weeks; This spontaneous case was reported by an other health care professional and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Patient administered the 2nd bivalent dose to a patient 6 weeks after the 1st one instead of 8 weeks) and NO ADVERSE EVENT (No adverse event) in a 74-year-old female patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. GJ3274) for COVID-19 prophylaxis.     No Medical History information was reported.   On 23-Mar-2023, the patient received fourth dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On 12-May-2023, received fifth dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) dosage was changed to 1 dosage form. On 12-May-2023,  after starting mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)), the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Patient administered the 2nd bivalent dose to a patient 6 weeks after the 1st one instead of 8 weeks). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Patient administered the 2nd bivalent dose to a patient 6 weeks after the 1st one instead of 8 weeks) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Patient administered the 2nd bivalent dose to a patient 6 weeks after the 1st one instead of 8 weeks).    No concomitant medications were reported.  The patient did not receive any other vaccines in the 4 weeks prior to COVID-19 vaccine.  No treatment medications were reported.   This case was linked to US-MODERNATX, INC.-MOD-2023-724230 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2023-724230:(Monovalent Case)
Patient states face, neck, and part of upper chest turned red and itchy within hours of administration. Slowly faded after 4 days. She had hydroxyzine at home and took that on Days 3 and 4 to relieve itchiness.